Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic, Nicole Blijlevens, Yok-Lam Kwong, Uzma Zaidi, Fausto Castagnetti, Paolo Gallipoli, Maria Cristina Miggiano, Peter E Westerweel, Melissa Chen, M. Carmen Garcia Hernandez, William J. Kell, Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth, Germano Ferreira, Jeroen J.W.M. Janssen

Blood (2023) 142 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2023-181937

Published: 2023

Journal Articles

Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification

Harinder Gill, Lester Au, Garret Man Kit Leung, Dorothy Tsai, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Albert Chun Fung Sin, Hsin An Hou, Chih-Cheng Chen, Yok Lam Kwong

Blood (2023) 142 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2023-180922

Published: 2023

Journal Articles

Glofitamab in Aggressive B Non-Hodgkin Lymphoma (B-NHL): A Real World Experience

Thomas Chan, Yok Lam Kwong, Eric Tse

Blood (2023) 142 (Supplement 1): 6254.

https://doi.org/10.1182/blood-2023-173916

Published: 2023

Journal Articles

Efficacy and Safety of Asciminib in Chinese Patients with Philadelphia Chromosome(Ph)-Positive Leukaemias

Yuk Man Cheung, Yok-Lam Kwong

Blood (2023) 142 (Supplement 1): 6383.

https://doi.org/10.1182/blood-2023-185578

Published: 2023

Journal Articles

A Clinical-Molecular Prognostic Scoring System for Myelodysplastic Syndrome in Asia - a Multicenter Study of the Asian Myeloid Working Group (AMWG)

Harinder Gill, Hsin An Hou, Paul Lee, Rita Yim, Xavier Cheng-Hong Tsai, Melissa Ooi, Tsz-Shing Hui, Radha Raghupathy, Lynn Chin, Lester Au, Vivian Li, Garret Man Kit Leung, Edmond Ma, Asif Javed, Ho-Wan Ip, Wee-Joo Chng, Wen-Chien Chou, Hwei-Fang Tien, Yok-Lam Kwong

Blood (2023) 142 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2023-182750

Published: 2023

Journal Articles

Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis

Harinder Gill, Lester Au, Garret Man Kit Leung, Dorothy Tsai, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Rock Yuk Yan Leung, Elaine Lee, Hugh Young Rienhoff Jr., Yok Lam Kwong

Blood (2023) 142 (Supplement 1): 621.

https://doi.org/10.1182/blood-2023-181971

Published: 2023

Journal Articles

An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial

Harinder Gill, Rita Yim, Lynn Chin, Paul Lee, Vivian Li, Lester Au, Garret Man Kit Leung, Ka Leung Daniel Cheuk, Shau-Yin Ha, Chi Kong Li, Melissa Ooi, Wee-Joo Chng, Patrick Chu, Cyrus Kumana, Yok Lam Kwong

Blood (2023) 142 (Supplement 1): 157.

https://doi.org/10.1182/blood-2023-179644

Published: 2023

Journal Articles

Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis

Harinder Gill, Lester Au, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Garret MK Leung, Carmen Lee, Tony Kwun Yat Wu, Cheong Ngai, Ryan Ho, Albert Chun Fung Sin, Hsin-An Hou, Chih-Cheng Chen, Yok-Lam Kwong

Blood (2022) 140 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2022-169613

Published: 2022

Journal Articles

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 2063–2065.

https://doi.org/10.1182/blood-2022-158612

Published: 2022

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis

Blood (2021) 138 (Supplement 1): 2403.

https://doi.org/10.1182/blood-2021-148807

Published: 2021

Journal Articles

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Burhan Ferhanoglu, Marta Zerga, Mubarak Al-mansour, Tae Min Kim, Su-Peng Yeh, Yuqin Song, Amado J Karduss, Gayane Tumyan, Soon Thye Lim, Silvia Rivas-Vera, Yok Lam Kwong, Kwang-Wei Wu, Zhongwen Huang, Mark Hertzberg

Blood (2021) 138 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2021-145838

Published: 2021

Journal Articles

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Noriko Fukuhara, Won Seog Kim, Dok Hyun Yoon, Eiju Negoro, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai

Blood (2021) 138 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2021-145512

Published: 2021

Journal Articles

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Burhan Ferhanoglu, MD, Tae Min Kim, MD PhD, Amado Karduss, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Gayane Tumyan, Mubarak Al Mansour, Marta Zerga, MD, Yuqin Song, MD PhD, Silvia Rivas-Vera, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, Su-Peng Yeh, MD, Arif Abdillah, MD, Zhongwen Huang, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg, MBBS PhDFRACP FRCPA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-134885

Published: 2020

Journal Articles

A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

Chunxiao Zhang, Garret MK Leung, MBBS, Sze Pui Tsui, MSc, Ho-Wan Ip, MBBS,FRCPA, Edmond S. K. Ma, MD, Chun Hang Au, PhD, Chris T.L. Chan, PhD, Ka Lam Nelson Ng, PhD, Sze Fai Yip, MD, Bonnie Kho, MD, Harold K K Lee, MD, Qing LIU, Thomas Wing Yan Leung, Yok Lam Kwong, MD FRCP, Anskar Yu Hung Leung, MD PhD

Blood (2019) 134 (Supplement_1): 3825.

https://doi.org/10.1182/blood-2019-126510

Published: 2019

Journal Articles

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Harinder Gill, FRCP, FRCPath, Rita Yim, PhD, Cyrus R Kumana, FRCP, Yok-Lam Kwong, MD

Blood (2019) 134 (Supplement_1): 3853.

https://doi.org/10.1182/blood-2019-125185

Published: 2019

Journal Articles

A Mutation Pentad Defined Outcome of De Novo and Cytogenetically Normal Acute Myeloid Leukaemia in Young Adults

Blood (2019) 134 (Supplement_1): 1400.

https://doi.org/10.1182/blood-2019-130810

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai

Blood (2019) 133 (2): 137–146.

https://doi.org/10.1182/blood-2018-04-848044

Published: 2019

Includes: Supplemental data

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study

Won-Seog Kim, Hyeon-Seok Eom, Su-Peng Yeh, MD, Seok-Goo Cho, MD PhD, Dae Seog Heo, MD, Jin Seok Kim, MD PhD, Ming Yao, MD, Jun Zhu, Grace Gao, Lijia Zhang, Ming Qi, MD PhD, Huiqiang Huang, Yok Lam Kwong, MD FRCP

Blood (2018) 132 (Supplement 1): 1617.

https://doi.org/10.1182/blood-2018-99-111885

Published: 2018

NARROW

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification

Glofitamab in Aggressive B Non-Hodgkin Lymphoma (B-NHL): A Real World Experience

Efficacy and Safety of Asciminib in Chinese Patients with Philadelphia Chromosome(Ph)-Positive Leukaemias

A Clinical-Molecular Prognostic Scoring System for Myelodysplastic Syndrome in Asia - a Multicenter Study of the Asian Myeloid Working Group (AMWG)

Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis

An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial

Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

A Mutation Pentad Defined Outcome of De Novo and Cytogenetically Normal Acute Myeloid Leukaemia in Young Adults

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only